Comparative Pharmacology
Head-to-head clinical analysis: ALVESCO versus ARMONAIR DIGIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALVESCO versus ARMONAIR DIGIHALER.
ALVESCO vs ARMONAIR DIGIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclesonide is a prodrug that is converted to the active metabolite des-ciclesonide, which has anti-inflammatory activity by binding to glucocorticoid receptors, thereby inhibiting inflammatory mediators such as cytokines and leukotrienes.
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
Inhalation: 160 mcg twice daily (morning and evening). May be increased to 320 mcg twice daily if inadequate response. Maximum 640 mcg twice daily.
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the systemically absorbed fraction; however, the receptor occupancy half-life is significantly longer due to lipophilic tissue binding, providing therapeutic duration of 12 hours.
Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state.
Primarily hepatic metabolism (CYP3A4) to less active metabolites; renal excretion accounts for <10% unchanged; fecal excretion as metabolites ~80%.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30%
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid